CERo Therapeutics Fails to Secure Nasdaq Listing, Pursues OTC Market Options
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Source: SeekingAlpha
Nasdaq Listing Denial: CERo Therapeutics received a determination letter from the Nasdaq Hearings Panel denying its request to continue listing its shares due to non-compliance with the required stockholders’ equity of at least $2.5 million.
Appeal and Alternatives: The company plans to appeal the decision to the Nasdaq Listing and Hearing Review Council and is considering listing its shares on the OTC Markets while continuing its clinical operations.
Stock Price Decline: Following the announcement, CERo's stock price plummeted by 72%, closing at $0.51 during after-market trading.
Additional Information: The article also references Seeking Alpha’s Quant Rating and historical financial data for CERo Therapeutics Holdings, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
